Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Bristol-Myers Squibb selectively targets TYK2 for autoimmune, inflammatory diseases

Aug. 30, 2017

Hair follicle stem cell metabolism can be exploited to activate the hair cycle

Aug. 30, 2017

Coherus reports findings from pharmacokinetic study of adalimumab biosimilar CHS-1420

Aug. 29, 2017

New phase IIa trial tests S. hominis lotion for atopic dermatitis

Aug. 23, 2017

Dr. Reddy's reports out-licensing of DFD-06 to Encore Dermatology

Aug. 22, 2017

Ilkos Therapeutic initiates phase II study of S-42909 for leg ulcer healing

Aug. 22, 2017

Patient recruitment underway in phase II trial of SK-1405 in subjects with uremic pruritus

Aug. 21, 2017

Anti-TNF therapy corrects dysregulation of the Th17:Treg cell axis in hidradenitis suppurativa

Aug. 16, 2017

Vitae Pharmaceuticals divulges new nuclear receptor ROR-gamma modulators

Aug. 16, 2017

Boehringer Ingelheim patents nuclear receptor RORgamma antagonists

Aug. 7, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....